Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
2016 · New England Journal of Medicine · 1,957 citations
https://doi.org/10.1056/nejmoa1609709
L
Lowell L. Hart
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
206
Papers
10.3K
Citations
44
h-index
87
i10-index
Lowell L. Hart is an academic researcher from Atrium Health Wake Forest Baptist. The author has contributed to research in topics: Advanced Breast Cancer Therapies & Lung Cancer Research Studies & HER2/EGFR in Cancer Research. The author has an h-index of 44, co-authored 176 publications.
Papers by this author
worksMyelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial
2019 · Annals of Oncology · 161 citations
https://doi.org/10.1093/annonc/mdz278
Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study
2020 · Advances in Therapy · 121 citations
https://doi.org/10.1007/s12325-020-01538-0
Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2− Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1)
2021 · Clinical Cancer Research · 111 citations
https://doi.org/10.1158/1078-0432.ccr-20-2114
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial
2017 · Breast Cancer Research and Treatment · 108 citations
https://doi.org/10.1007/s10549-017-4518-8
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer
2021 · British Journal of Cancer · 86 citations
https://doi.org/10.1038/s41416-021-01415-9
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat